Discover
NNVC
NanoViricides, Inc.
1.35
200 x 1.21
300 x undefined
bid
ask
-
0.03
2.17%
250 @ 06:04 AM
1.24 -0.11 (8.15%)
| Ytd | 19.47% | |
| 1y | -3.57% |
1.33
day range
1.40
0.85
52 week range
2.23
| Open | 1.38 | Prev Close | 1.38 | Low | 1.33 | High | 1.40 | Mkt Cap | 31.03M |
| Vol | 174.05K | Avg Vol | 908.84K | EPS | -0.44 | P/E | N/A | Forward P/E | -2.68 |
| Beta | 0.97 | Short Ratio | 1.92 | Inst. Own | 9.42% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-15 | 50-d Avg | 1.44 | 200-d Avg | 1.29 | 1yr Est | 6.50 |
NNVC News
benzinga.com
FDA's Office Of Orphan Products Development Grants Rare Pediatric Disease Drug Designation To NanoVi
NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a c
accessnewswire.com
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles
SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE
benzinga.com
NanoViricides Ships NV-387 Oral Gummies To The Democratic Republic of Congo Ahead Of Patient Enrollm
Clinical Trial Site preparations are being performed by our CRO in India, Om Sai Clinical Research P
benzinga.com
NanoViricides' Proposal To Perform Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For C
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antivira
benzinga.com
NanoViricides Proposes Phase II Clinical Study Of NV-387 Oral Gummies To Congo To Treat Current Bund
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing
benzinga.com
NanoViricides Files Prospectus For Offering $50M Mixed Shelf
https://www.sec.gov/Archives/edgar/data/1379006/000110465926071007/tm2616485d1_s3.htm